The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
Abstract
PURPOSE: Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC. MATERIALS AND METHODS: This was a multicenter, randomized, open-label, parallel group, phase III trial. Patients with primary treatment-naive or initial recurrent advanced HCC after surgery were randomly assigned (1:1) to receive LEN plus on-demand TACE (LEN-TACE) or LEN monotherapy. LEN was initiated within 3 days after random assignment (initial dose: 12 mg once daily for patients ≥ 60 kg; 8 mg once daily for patients < 60 kg). TACE was initiated one day after LEN initiation. The primary end point was overall survival (OS). RESULTS: Between June 2019 and July 2021, a total of 338 patients underwent random assignment at 12 centers in China: 170 to LEN-TACE and 168 to LEN. At a prespecified event-driven interim analysis after a median follow-up of 17.0 months, the median OS was significantly longer in the LEN-TACE group (17.8 v 11.5 months; hazard ratio, 0.45; P < .001). The median progression-free survival was 10.6 months in the LEN-TACE group and 6.4 months in the LEN group (hazard ratio, 0.43; P < .001). Patients in the LEN-TACE group had a higher objective response rate according to the modified RECIST (54.1% v 25.0%, P < .001). Multivariable analysis revealed that portal vein tumor thrombus and treatment allocation were independent risk factors for OS. CONCLUSION: The addition of TACE to LEN improves clinical outcomes and is a potential first-line treatment for patients with advanced HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Second, LEN promotes tumor vascular normalization, which would be expected to enhance response rates by improving embolism agent delivery and optimizing the embolization effect,(24) as well as optimizing delivery of systemic anticancer drugs within the tumor through reduction of tumor vascular permeability and interst…”
BackgroundKudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
(2011) · Hepatogastroenterology · doi:10.5754/hge11753 · Cited by 2,435
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. H. (2016) · Hepatology · doi:10.1002/hep.28453 · Cited by 732
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507 · cited 1×
“It is known that TACE induces the upregulation of proangiogenic factors by creating an ischemic tumor environment.(14,15) LEN is a multikinase inhibitor that targets vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor a, RET, and KIT, all of…”
BackgroundTransarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Shim, J. H., Park, J., Kim, J. H., An, M., Kong, S., Nam, B., Choi, J., Kim, H. B., Lee, W. J., & Kim, C. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00909.x · Cited by 239
Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G. S., Ikeda, M., Lim, H.-Y., Ho, G. F., Choo, S. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.12.001 · Cited by 234
Fu, Z., Li, X., Zhong, J., Chen, X., Cao, K., Ding, N., Liu, L., Zhang, X., Zhai, J., & Qu, Z. (2021) · Hepatology International · doi:10.1007/s12072-021-10184-9 · Cited by 167
Vogl, T. J., Naguib, N. N. N., Nour-Eldin, N.-E. A., Rao, P. P., Emami, A. H., Zangos, S., Nabil, M. M., & Abdelkader, A. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.08.007 · Cited by 152
Kano, M. R., Komuta, Y., Iwata, C., Oka, M., Shirai, Y.-T., Morishita, Y., Ouchi, Y., Kataoka, K., & Miyazono, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01003.x · Cited by 125
Yoo, D., Kim, K. M., Jin, Y., Shim, J. H., Ko, G., Yoon, H., Sung, K., Lee, J., Kang, Y., Lim, Y., et al. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06341.x · Cited by 124
Kawamura, Y., Kobayashi, M., Shindoh, J., Kobayashi, Y., Okubo, S., Tominaga, L., Kajiwara, A., Kasuya, K., Iritani, S., Fujiyama, S., et al. (2020) · Liver Cancer · doi:10.1159/000510299 · Cited by 73
Xiao, X., Lau, W. Y., Wu, Z., Zhao, C., Ma, Y., Xiang, B., Zhu, J., Zhong, J., & Li, L. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.03.042 · Cited by 69
Gardini, A. C., Scartozzi, M., Tada, T., Yoo, C., Shimose, S., Masi, G., Lonardi, S., Frassineti, L. G., Silvestris, N., Piscaglia, F., et al. (2021) · Liver International · doi:10.1111/liv.14817 · Cited by 69
Sun, H., & Zhu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.772195 · Cited by 59
Cited by
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“…demonstrated superior survival with the combination of camrelizumab and rivoceranib versus sorafenib, [326] TACE plus lenvatinib versus lenvatinib [327] and noninferior survival of tislelizumab versus sorafenib [328] ; however, it is unclear if these therapies apply to patients in the Western…”
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., Beal, E., Finn, R. S., Gade, T. P., Goff, L., Gupta, S., Guy, J., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 312
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Chan, S. L., Dawson, L. A., Kelley, R. K., Llovet, J. M., Meyer, T., Ricke, J., Rimassa, L., Sapisochin, G., Vilgrain, V., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.006 · Cited by 281
Metadata
- Authors
- Peng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., Cheng, Y., Huang, Z., Liang, Y., Fan, H., Qiao, L., Li, F., Zhuang, W., Peng, B., Wang, J., Li, J., & Kuang, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-01-01
- Volume
- 41
- Issue
- 1
- Pages
- 117-127
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4289654165
- Cited by
- 460
- References
- 25
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.